This question is currently the subject of an NRG Oncology trial (https://clinicaltrials.gov/ct2/show/NCT05050084) and I would encourage participation so that we can get a data-driven answer to this important question as soon as possible. Outside of the context of a trial, I do not currently use gene...

ASCO GU 2022: Validation of the Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer in the Phase III Randomized Trial NRG Oncology/RTOG 0126 (urotoday.com) The analysis referenced above showed that for men with intermediate risk prostate cancer treated with ra...

Also, the Multi-Modal AI (MMAI) predictive biomarker tool (commercially www.Artera.AI) is being validated in NRG/RTOG 9408 for the need of short-term ADT. A summary by Dr. @Daniel E. Spratt is here. The hope is that MMAI can be a predictive biomarker, which is currently unavailable for prostate...

Agree with Dr. @Mitchell S. Anscher above. The assays are prognostic but lack robust predictive validation making the interpretation of results challenging. Thus I would encourage enrollment on NRG GU010 for intermediate and GU009 for high-risk.

I’d like to, for borderline patients, if covered by insurance.